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ABSTRACT 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
aztreonam lysine for inhalation is effective in the treatment of patients with cystic fibrosis and 
Pseudomonas aeruginosa airway infection. 
 
STUDY DESIGN: Review of three English language primary randomized controlled trials 
published in 2008, 2009, and 2011. 
 
DATA SOURCES: Three randomized, double-blind, placebo-controlled studies using Cochrane 
and Pubmed databases. 
 
OUCOMES MEASURED: Patient oriented outcomes measured included change in respiratory 
symptoms measured by the Cystic Fibrosis Questionnaire-Revised and need for additional 
antipseudomonal antibiotics indicative of pulmonary exacerbation. 
 
RESULTS: In both cystic fibrosis (CF) patients who have been treated with standard long term 
therapy and those who have not, 28 day therapy with aztreonam lysine for inhalation (AZLI) was 
shown to be effective in the treatment of chronic Pseudomonas aeruginosa airway infection. 
AZLI treatment showed statistical significance in the improvement of patient reported 
respiratory symptoms compared to placebo. Twice per day versus three times per day dosing did 
not show a significant impact on outcome. In CF patients with mild respiratory dysfunction, 
determined by a FEV1 of > 75%, AZLI treatment did not significantly prevent need for 
additional antipseudomonal antibiotics during the course of the study. 
 
CONCLUSION: These studies determined that AZLI is more effective at reducing respiratory 
symptoms in CF patients with chronic P. aeruginosa airway infection than placebo. AZLI 
therapy does not significantly decrease the number of severe pulmonary exacerbations that 
would require further antipseudomonal antibiotics. Twice or three times per day dosing does not 
significantly affect the outcomes. 
 
KEY WORDS: aztreonam, monobactam, cystic fibrosis, Pseudomonas aeruginosa
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INTRODUCTION 
 Cystic fibrosis (CF) is a chronic, autosomal recessive disease of the secretory glands.1,2 It 
is characterized by increased pulmonary secretions which are especially thick and difficult to 
clear.1 Common complications include superimposed airway infections and pancreatic 
insufficiency due to mucus blocked ducts.1 The most common pathogen of airway infections in 
CF patients, and one of the most difficult to eradicate, is Pseudomonas aeruginosa (P. 
aeruginosa).1 Chronic airway infections are associated with a progressive decrease in lung 
function and overall increased patient morbidity and mortality.1 
 Due to the recessive pattern of inheritance for CF, an affected individual must acquire 
one abnormal gene from each parent. Approximately 30,000 people in the United States are 
affected by CF, however, over 10 million Americans are carriers of the abnormal cystic fibrosis 
transmembrane conductance regulator (CFTR) gene.2, 3  This condition affects all races, 
ethnicities and genders, but is most commonly found among Northern Europeans.2 The precise 
cost of treating CF in recent years is unknown, however data from 1996 shows the direct cost per 
patient per year was up to $16,300 and lifetime direct costs were between $200,000 and 
$300,000.4 The exact number of healthcare visits per year for CF patients has not been explicitly 
calculated, however the recommendation is for quarterly evaluations, not including visits or 
hospitalizations for worsening symptoms or pulmonary exacerbations, medication changes, 
social work visits or dietary evaluations.5 
 CF is caused by an inherited defect in the CFTR gene that encodes for an ion channel 
protein responsible for controlling salt and water movement within the cell.2 There are a wide 
variety of known mutations that can affect the function of the CFTR gene, however all create a 
dysfunctional protein which results in thick, persistent mucus secretions.2 Symptoms involve the 
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sinuses, lungs, skin, liver, pancreas, gastrointestinal tract and reproductive organs and include 
salty sweat, increased thick mucus production leading to chronic sinus and airway infections, 
dyspnea, pancreatitis, diabetes, malnutrition, and infertility.2 Respiratory failure is the most 
common cause of death in CF patients, and it is due to an accumulation of tissue damage from 
chronic and/or recurrent pulmonary infections.2 There is no known cure for CF at this time.3 
 Treatment of CF is multifactorial and involves a variety of body systems and treatment 
methods. Patients are instructed in a variety of airway clearance techniques including postural 
drainage, percussion, inflatable vests, pulmonary rehabilitation with exercise training, and 
breathing strategies.3,6 Inhaled medications such as mucolytics, antibiotics, bronchodilators and 
hypertonic saline, as well as oral or IV antibiotics in severe exacerbations, have been utilized for 
airway infections and worsening respiratory symptomatology.3,6 Nutrition is another focus, with 
supplementation implemented involving a high caloric diet, feeding tube, pancreatic enzyme 
supplementation and specific nutrient supplementation when medically necessary.3,6 Surgical 
procedures including nasal polyp removal, endoscopy with lavage, and lung transplantation are 
employed as a last resort to aid in respiratory function.3,6 
 Currently, tobramycin is the most commonly used inhaled antibiotic for exacerbations of 
respiratory infections in CF patients, and has been shown to be effective against P. aeruginosa.3,6 
Since aztreonam is a monobactam antibiotic that has also been shown to have antipseudomonal 
properties, many studies have begun to explore inhaled aztreonam lysine as a potential effective 
intervention to relieve symptoms and treat P. aeruginosa airway infection.
OBJECTIVE                                                                                                                                   
 The objective of this selective EBM review is to determine whether or not aztreonam 
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lysine for inhalation is effective in the treatment of patients with cystic fibrosis and 
Pseudomonas aeruginosa airway infection.
METHODS 
 Three randomized, double-blind, placebo-controlled studies were included in this 
selective EBM review. The studies involved males and females 6 years of age and older with 
established CF and P. aeruginosa airway infection. Inclusion criteria consisted of studies that 
were randomized, controlled, double blind and published after 1996, with patients that were 6 
years of age and older with current P. aeruginosa airway infections. Exclusion criteria comprised 
of patients under the age of 6 and those that utilized repeated courses of treatment with AZLI. 
The intervention was inhaled aztreonam lysine (AZLI) via nebulizer with a formulation 
of 75 mg of aztreonam and 52.5 mg of lysine monohydratae diluted in 1 mL of 0.17% NaCl. The 
comparison group received a visually matched placebo via nebulizer with a formulation of 5 mg 
lactose diluted in 1mL of 0.17% NaCl. Outcomes addressed included patient-reported impact on 
respiratory symptoms and symptom or health exacerbation requiring use of oral, IV or additional 
inhaled antipseudomonal antibiotics. Outcomes were measured by utilizing the CF 
Questionnaire-Revised where points ranged from 0-100 and increasing scores indicated 
improvement of symptoms, as well as explicitly counting patients who required use of added 
antipseudomonal antibiotics during the treatment or follow up period specified by the individual 
study. 
Author searched articles within PubMed and The Cochrane Central Register of 
Controlled Trials (CENTRAL) databases between 2012 and 2013. Searches were conducted 
using keywords “aztreonam,” “monobactam,” “cystic fibrosis,” and “Pseudomonas aeruginosa.” 
Included articles were published in English, in 2008, 2009 and 2011, and selected based on their
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relevance to CF patients with P. aeruginosa airway infections and because they addressed 
patient-oriented outcomes (POEMs). Each article was published in a peer-reviewed journal. 
Table 1 – Demographics and Characteristics of Included Studies 
Study Type # Pts Age Inclusion Criteria Exclusion Criteria W/D Intervention 
McCoy 
(2008)1 
Double
-blind 
RCT 
246 ≥ 6 
yrs 
old 
≥ 6 yrs old, 
documented CF, 
current P. 
aeruginosa 
airway infection, 
3+ tobramycin 
inhalation 
solution courses 
w/i last yr 
 
FEV1 ≥ 25% and 
≤ 75% predicted, 
arterial oxygen 
saturation ≥ 90% 
on room air 
- Current oral corticosteroid use, daily 
O2 supplementation or intolerance to 
the study’s medications  
- Recent changes in antimicrobial, 
bronchodilator, anti-inflammatory, 
corticosteroid medications or 
physiotherapy technique/schedule 
- Acute findings on chest radiograph w/i 
past 90 days, high AST, ALT, or SCr 
levels, or airway cultures of 
Burkholderia cepacia w/i past 2 yrs 
- Pregnant, lactating, lung transplant, or 
a medical or psychiatric illness 
interfering with study 
156 28 day 
course of 
tobramycin 
inhalation 
solution 
(TIS) 
followed by 
a 28 day 
course of 75 
mg AZLI 
with 
nebulizer 
BID or TID 
 
Retsch-
Bogart 
(2009)7 
Double
-blind 
RCT 
164 ≥ 6 
yrs 
old 
≥ 6 yrs old, 
documented CF, 
P. aeruginosa 
airway infection, 
FEV1 ≥ 25% to ≤ 
75% predicted, 
arterial oxygen 
saturation ≥ 90% 
on room air 
 
- Anti-pseudomonal antibiotic or 
azithromycin use w/i past 28 days 
- Current oral corticosteroid use, daily 
O2 supplementation >2 L/min at night 
or intolerance to the study’s 
medications 
- Recent changes to antimicrobial, 
bronchodilator, anti-inflammatory or 
corticosteroid medications or 
physiotherapy technique/schedule 
- Acute findings on chest radiograph w/i 
90 days, high AST, ALT, or SCr levels, 
or airway cultures of Burkholderia 
cepacia w/i past 2 yrs 
- Pregnant, lactating, lung transplant, or 
a medical or psychiatric illness that 
interferes with study 
40  28 day 
treatment 
course of 75 
mg 
aztreonam 
lysine for 
inhalation 
administere
d by 
nebulizer 
TID 
Wain-
wright 
(2011)8 
Double
-blind 
RCT 
160 ≥ 6 
yrs 
old 
≥ 6 yrs, 
documented CF, 
P. aeruginosa 
airway infection, 
FEV1 ≥ 75% 
predicted;   
≥ 2 chronic or 
intermittent CF 
symptoms for ≥ 
28 days before 
baseline 
- Pregnant, lactating, lung transplant, or 
a medical or psychiatric illness that 
interferes with study participation 
- Previous enrollment in AZLI trial, or 
acute findings on chest radiograph 
- Changes in antimicrobial, 
bronchodilator, or corticosteroid 
medications or physiotherapy 
technique/schedule w/i 7 days 
-Anti-pseudomonal antibiotic w/i past 
28 days 
-Intolerance to the study’s medications 
4 28 day 
course of 
AZLI with 
nebulizer 
TID (doses 
separated ≥ 
4 hrs) 
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 The statistics utilized from the article or calculated by the author included relative benefit 
increase (RBI), absolute benefit increase (ABI), number needed to treat (NNT), relative risk 
increase (RRI), absolute risk increase (ARI), number needed to harm (NNH), 95% confidence 
intervals (CI) and p-values. 
OUTCOMES MEASURED 
 There were a variety of outcomes addressed by each study, however the author utilized 
outcomes that served as POEM’s to address the research question.  
 McCoy et al (2008) included patients with significant lung disease (FEV1 ≥ 25% to ≤ 
75% predicted) and who had been compliant with the standard CF treatment of maintenance 
tobramycin inhalation solution (TIS) treatment courses in their study. All study participants were 
administered a 28 day course of open-label TIS (300 mg twice daily) and then randomized into a 
1:1:1 grouping of AZLI (75mg of aztreonam, 52.5 mg of lysine monohydrate diluted in 1 mL of 
0.17% NaCl solution) either twice or three times daily, or placebo (5 mg lactose diluted in 1 mL 
of 0.17% NaCl solution) via nebulizer for a treatment period of 28 days. Patients were monitored 
on Day 14, Day 28, and Days 42, 56, 70 and 84 during the follow up period. The outcome 
addressed was change in patient reported respiratory symptoms, measured by utilizing the Cystic 
Fibrosis Questionnaire-Revised (CFQ-R). Minimal clinically important difference (MCID) score 
of 5 was used by to analyze results as it corresponds to the smallest change in symptoms 
noticeable by patients. Therefore, a 5 point change or more indicated improved or worsened 
symptoms. At Day 28 of treatment, patients were categorized as improved ( ≥ 5 point increase 
from baseline CFQ-R Respiratory scores), worsened ( ≥ 5 point decrease from baseline)
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or stable/unchanged (< 5 point change). Comparisons between the experimental and the control 
groups were made throughout treatment and the designated follow up period. 
 Retsch-Bogart et al (2009) focused on patients with moderate to severe lung disease 
(determined by a FEV1 ≥ 25% to ≤ 75% predicted) who had not been administered any inhaled, 
IV, or oral anti-pseudomonas antibiotics, azithromycin or aerosolized hypertonic saline solution 
within the past 28 days prior to the date of screening. Patients were split into groups via a 1:1 
randomization, with the interventional group receiving 75 mg AZLI administered by nebulizer 
three times daily for 28 days and the control group receiving a visually matched placebo at the 
same interval for the same duration of time. The outcome addressed was change in patient 
reported respiratory symptoms, measured by the CFQ-R. Analysis of the questionnaire and 
MCID were the same as McCoy et al. Patients were followed throughout treatment and the 2 
week follow up period. Comparisons between the experimental and control groups were made. 
 Wainwright et al (2011) selected for patients with mild lung disease (FEV1 ≥ 75% 
predicted). Patients were randomly assigned (1:1) to treatment with 75 mg AZLI or placebo by 
nebulizer three times per day, doses separated by more than 4 hrs, for 28 days. Patients were 
monitored at Day 14, 28, and 42 for follow-up. The outcome was symptom(s) or health 
exacerbation requiring use of oral, IV, or additional inhaled antipseudomonal antibiotics during 
the study (28 day treatment period and 14 day follow up). The outcome was measured by 
explicitly counting the number of patients who required use of additional antipseudomonal 
antibiotics in the control and experimental groups. 
RESULTS 
 The focus of this EBM review is patient oriented outcome measures, so only those will be 
presented in the following section. Two of the randomized control trials, McCoy et al and
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 Retsch-Bogart et al, utilized the CFQ-R to determine patient reported respiratory symptoms as a 
means to evaluate the treatments. The third study assessed pulmonary exacerbation that required 
additional antipseudomonal antibiotics to determine patient outcome. 
In McCoy et al, of the 246 patients enrolled and assigned groups by a 1:1:1 
randomization, 211 completed the 28 day course of TIS and received at least 1 dose of AZLI or 
placebo, and therefore comprised the intention to treat population.1 173 patients (82%) 
completed the 28 day treatment, and 90 (43%) completed the follow-up period.1  
Responses of twice versus three times per day dosing placebo groups were pooled for the 
efficacy analyses and were compared with the AZLI-pooled group. Analysis of CFQ-R used the 
last observation carried forward convention. At the conclusion of treatment (Day 28), adjusted 
mean CFQ-R respiratory scores increased 5.01 points in the AZLI-pooled group compared to 
placebo (95% CI, 0.81 to 9.21; P = 0.020), showing significance for AZLI in decreasing 
respiratory symptoms versus placebo.1 During the treatment period, the AZLI-treated patients 
had more improved CFQ-R respiratory scores and less worsened respiratory scores compared 
with placebo-treated patients (overall categorical comparison, P = 0.029).1 52% of AZLI treated 
patients and 37% of placebo had a greater than 5 point increase in respiratory score and 28% of 
AZLI versus 38% of placebo had a greater than 5 point decrease in respiratory score.1 For 
improved CFQ-R scores, the RBI was calculated to be 40.54%, the ABI was 15% and the NNT 
was seven (Table 2). Therefore, for every 7 patients treated with AZLI, one more patient showed 
improved respiratory symptoms compared to the control. For worsened CFQ-R scores, the 
calculated RRI was -26.32%, the ARI was -10% and the NNH was -10 patients (Table 3). This 
means that for every 10 patients treated with AZLI, one less had worsened respiratory symptoms.  
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Table 2. Improved Respiratory Score on CRQ-R During Treatment Period (Day 0-28)1 
CER EER RBI ABI NNT 
37% 52% 41% 15% 7 patients 
 
Table 3. Worsened Respiratory Score on CRQ-R During Treatment Period (Day 0-28)1 
CER EER RRI ARI NNH 
38% 28% -26% -10% -10 patients 
 
 The study of Retsch-Bogart, et al focused on patients without recent use of 
antipseudomonal antibiotics or azithromycin and had a primary efficacy endpoint of change in 
patient reported respiratory symptoms analyzed through the use of the CFQ-R scale. Patients 
were randomly assigned (1:1) a 28 day treatment of 75 mg AZLI or placebo at three times per 
day dosing and monitored throughout treatment and a 14 day follow up period.7 Of the 164 
patients who enrolled and began treatment, 138 completed the 28 day treatment period and 124 
(76%) completed the study through the follow-up.7 At day 28, patients were categorized as 
improved, worse, or stable based on their change from baseline CFQ-R respiratory scores. Five 
point or greater changes were determined to be the minimal clinically important difference and 
used to dichotomize the patient data into the categories by Retsch-Bogart, et al.7   
 The adjusted mean CFQ-R respiratory scores showed a significant improvement in the 
AZLI group and decline in the placebo group at Day 28, the conclusion of the treatment period 
(9.7 point difference, 95% CI, 4.3 to 15.1; P < 0.001).7 Also established at the conclusion of 
treatment, the data showed AZLI was shown to be significantly better in improving CFQ-R 
respiratory scores, and less likely to cause worsened respiratory scores, compared to the placebo 
group (P = 0.006 for overall comparison).7 In the AZLI group, 56% showed a greater than 5 
point increase in respiratory score and 25% showed a greater than 5 point decrease in respiratory 
score, compared with the placebo group of 37% and 45%, respectively.7 The calculated NNT 
was 6, meaning that for every 6 patients treated with AZLI, one more had improved respiratory
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 symptoms (Table 4). The calculated NNH was -5, meaning that for every 5 patients treated with 
AZLI, one less patient will have worsened respiratory symptoms (Table 5). 
Table 4. Improved Respiratory Score on CRQ-R at Treatment End (Day 28)7 
CER EER RBI ABI NNT 
37% 56% 51% 19% 6 patients 
 
Table 5. Worsened Respiratory Score on CRQ-R at Treatment End (Day 28)7 
CER EER RRI ARI NNH 
45% 25% -44% -20% -5 patients 
 
 In Wainwright, et al, patients were treated with 28 days of 75 mg AZLI or placebo at 
three times per day dosing and followed for an additional 14 days.8 The study enrolled and 
randomly assigned 160 patients, 156 (98%) of which completed the study.8 Efficacy was 
assessed by comparing the number of patients that required additional oral, IV, or inhaled 
antibiotics during the treatment period and follow up. The need for additional antibiotics was 
similar amongst both the experimental and control groups from baseline through the follow up 
period (AZLI, 25%; placebo, 25.9%; p >0.999).8 AZLI treatment did not significantly prevent 
symptoms or health exacerbations requiring additional antibiotics. The calculated NNH was -
112. This means that for every 112 patients treated with AZLI, one less will require additional 
antipseudomonal antibiotics than compared to the control (Table 6) 
Table 6. Need for Additional Antipseudomonal Antibiotics During Study8 
CER EER RRI ARI NNH 
25.9% 25% 3.5% 0.9% -112 patients 
 
DISCUSSION 
 To summarize the data within the three studies analyzed, it can be concluded that 75 mg 
of AZLI is effective at reducing respiratory symptoms in CF patients with chronic P. aeruginosa 
airway infection and moderate to severe respiratory dysfunction (FEV1 between 25% and 75% 
predicted) compared to placebo. AZLI therapy did not significantly decrease the severe
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 pulmonary exacerbations that would require further antipseudomonal antibiotics in patients with 
mild respiratory dysfunction, or a FEV1 > 75% predicted. However, in the study that evaluated 
need for additional antibiotics, patients had a modest symptomatic baseline, and therefore any 
deviation from that may have prompted patients to seek additional treatment whether they truly 
needed it or not. 
There were several limitations and flaws in the three research studies. While this EBM 
review included a population of CF patients over the age of 6, all three of these studies had 
significantly more adults participate than children. The study performed by McCoy, et al 
specifically had 78% of their participants over the age of 18.1 Retsch-Bogart, et al utilized a 
population where 77.4% were over the age of 18. As a general rule, along with standards of care 
at this point in time, more adults than children will have the moderate to severe lung impairment 
necessary to enter this specific study, and their disease progression may be more responsive to 
treatment. Therefore, these two studies may conclude a greater efficacy for children <18 years 
old than might be accurate. Also with Retsch-Bogart, et al, the participants were treated with TIS 
before AZLI or placebo. This makes it difficult to state clearly whether AZLI alone showed 
significant benefit to patients, or if it was the adjunctive treatment with TIS that provided 
significant symptom improvement. 
 Two of the three studies in this EBM review shared a significant patient drop out rate. 
While there were a wide variety of reasons as to the cause, poor patient compliance is a large 
issue both in research and in the medical field. In the United States, as of 2005, of the long term 
treatments currently available, specifically TIS or macrolide therapy, 46% of eligible CF patients 
over the age of 6 were not receiving maintenance treatment.7 In addition, patient compliance 
rates were less than ideal, ranging from 51% in older patients to 73% in younger individuals.7
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 Researchers and medical professionals need to work together with patients to develop additional 
treatment options for patients with chronic P. aeruginosa airway infection and emphasize the 
importance of treatment compliance for reducing morbidity and mortality. 
CONCLUSION 
According to the data generated from the three research studies compiled in this systemic 
review, AZLI has shown to be an effective treatment for patients with CF and chronic P. 
aeruginosa airway infection, whether pretreated with TIS and received proper maintenance 
therapy or not.  
Future research studies need to address whether inhaled antibiotic monotherapy is more 
efficacious in preventing pulmonary exacerbations and treating P. aeruginosa airway infections 
or if multiple products would provide greater benefit to patients.  A longitudinal study to assess 
patient health both pre- and post-treatment periods with inhaled antibiotics, and to determine if 
multiple treatments would be more or less valuable to CF patients with chronic P. aeruginosa 
airway infection would be a useful undertaking. AZLI evaluated in the short term in these three 
studies has shown to be effective, but further investigation is necessary to determine if its’ use as 
a long-term suppressive therapy would be beneficial. 
 Cystic fibrosis is a challenging condition to treat. Pulmonary involvement is debilitating 
for patients with regards to their ability to carry out daily activities. P. aeruginosa is notorious 
for being difficult to eradicate and responsible for increased mortality of those infected.1 
However, medical professionals have limited antibiotics that have shown to be both safe and 
effective in P. aeruginosa treatment. With continued research and patient compliance, CF 
patients will have improved quality of life and clinical outcomes.
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